vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Krystal Biotech, Inc. (KRYS). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $107.1M, roughly 5.6× Krystal Biotech, Inc.). Krystal Biotech, Inc. runs the higher net margin — 48.0% vs 40.8%, a 7.1% gap on every dollar of revenue. On growth, Krystal Biotech, Inc. posted the faster year-over-year revenue change (17.5% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $75.4M). Over the past eight quarters, Krystal Biotech, Inc.'s revenue compounded faster (53.8% CAGR vs 18.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Krystal Biotech, Inc. is a clinical-stage biotechnology company specializing in the research, development and commercialization of novel gene therapies for rare, serious dermatological diseases with high unmet medical needs. It primarily serves patients across North America and Europe, focusing on monogenic skin disorders that lack effective standard treatment options.
EXEL vs KRYS — Head-to-Head
Income Statement — Q4 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $107.1M |
| Net Profit | $244.5M | $51.4M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 41.5% |
| Net Margin | 40.8% | 48.0% |
| Revenue YoY | 5.6% | 17.5% |
| Net Profit YoY | 74.8% | 13.0% |
| EPS (diluted) | $0.89 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $107.1M | ||
| Q3 25 | $568.3M | $97.8M | ||
| Q2 25 | $555.4M | $96.0M | ||
| Q1 25 | $566.8M | $88.2M | ||
| Q4 24 | — | $91.1M | ||
| Q3 24 | $539.5M | $83.8M | ||
| Q2 24 | $637.2M | $70.3M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $51.4M | ||
| Q3 25 | $184.8M | $79.4M | ||
| Q2 25 | $159.6M | $38.3M | ||
| Q1 25 | $139.9M | $35.7M | ||
| Q4 24 | — | $45.5M | ||
| Q3 24 | $118.0M | $27.2M | ||
| Q2 24 | $226.1M | $15.6M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 41.5% | ||
| Q3 25 | 37.6% | 42.3% | ||
| Q2 25 | 33.6% | 40.9% | ||
| Q1 25 | 28.8% | 41.0% | ||
| Q4 24 | — | 45.4% | ||
| Q3 24 | 25.2% | 26.8% | ||
| Q2 24 | 43.3% | 12.2% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 48.0% | ||
| Q3 25 | 32.5% | 81.2% | ||
| Q2 25 | 28.7% | 39.9% | ||
| Q1 25 | 24.7% | 40.5% | ||
| Q4 24 | — | 49.9% | ||
| Q3 24 | 21.9% | 32.4% | ||
| Q2 24 | 35.5% | 22.2% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $1.69 | ||
| Q3 25 | $0.65 | $2.66 | ||
| Q2 25 | $0.55 | $1.29 | ||
| Q1 25 | $0.47 | $1.20 | ||
| Q4 24 | — | $1.53 | ||
| Q3 24 | $0.40 | $0.91 | ||
| Q2 24 | $0.77 | $0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $496.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $1.2B |
| Total Assets | $2.8B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $496.3M | ||
| Q3 25 | $791.1M | $392.6M | ||
| Q2 25 | $1.0B | $353.8M | ||
| Q1 25 | $1.1B | $308.8M | ||
| Q4 24 | — | $344.9M | ||
| Q3 24 | $1.2B | $374.0M | ||
| Q2 24 | $1.0B | $345.8M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.2B | ||
| Q3 25 | $2.0B | $1.1B | ||
| Q2 25 | $2.1B | $1.0B | ||
| Q1 25 | $2.2B | $984.7M | ||
| Q4 24 | — | $946.4M | ||
| Q3 24 | $2.3B | $885.8M | ||
| Q2 24 | $2.1B | $838.9M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $1.3B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.8B | $1.1B | ||
| Q1 25 | $2.9B | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $3.0B | $982.3M | ||
| Q2 24 | $2.8B | $917.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $77.5M |
| Free Cash FlowOCF − Capex | $332.4M | $75.4M |
| FCF MarginFCF / Revenue | 55.5% | 70.4% |
| Capex IntensityCapex / Revenue | 0.2% | 2.0% |
| Cash ConversionOCF / Net Profit | 1.36× | 1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $188.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $77.5M | ||
| Q3 25 | $49.0M | $39.7M | ||
| Q2 25 | $211.4M | $52.7M | ||
| Q1 25 | $240.3M | $31.0M | ||
| Q4 24 | — | $52.8M | ||
| Q3 24 | $271.3M | $58.9M | ||
| Q2 24 | $119.5M | $-4.2M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $75.4M | ||
| Q3 25 | $46.2M | $38.0M | ||
| Q2 25 | $208.5M | $50.8M | ||
| Q1 25 | $236.3M | $24.8M | ||
| Q4 24 | — | $52.0M | ||
| Q3 24 | $263.1M | $57.8M | ||
| Q2 24 | $113.0M | $-5.3M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 70.4% | ||
| Q3 25 | 8.1% | 38.8% | ||
| Q2 25 | 37.5% | 52.9% | ||
| Q1 25 | 41.7% | 28.1% | ||
| Q4 24 | — | 57.1% | ||
| Q3 24 | 48.8% | 69.0% | ||
| Q2 24 | 17.7% | -7.5% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 2.0% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.5% | 2.0% | ||
| Q1 25 | 0.7% | 7.0% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | 1.5% | 1.2% | ||
| Q2 24 | 1.0% | 1.6% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.51× | ||
| Q3 25 | 0.27× | 0.50× | ||
| Q2 25 | 1.32× | 1.38× | ||
| Q1 25 | 1.72× | 0.87× | ||
| Q4 24 | — | 1.16× | ||
| Q3 24 | 2.30× | 2.17× | ||
| Q2 24 | 0.53× | -0.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
